RedHill Biopharma (RDHL) announced that it has received its first Talicia ex-U.S. sales milestone, royalties and other payments totaling approximately $1.1M.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDHL:
- RedHill Biopharma Granted Nasdaq Compliance Extension
- RedHill Biopharma Gains FDA Support for Innovative Crohn’s Disease Therapy
- RedHill Biopharma receives positive FDA feedback for RHB-204 in Crohn’s Disease
- RedHill Biopharma Initiates Phase 2 Prostate Cancer Study
- RedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide study